Literature DB >> 2449643

Retinal pigment epithelial tears. Patterns and prognosis.

J H Yeo1, S Marcus, R P Murphy.   

Abstract

Increasing experience with the diagnosis of retinal pigment epithelial (RPE) tears has led to expanded recognition and understanding of this clinical entity. The authors report 18 RPE tears followed for an average of 28 months; 16 were associated with age-related macular degeneration and 2 with presumed ocular histoplasmosis syndrome. Retinal pigment epithelial dehiscences fell into four categories: nine spontaneous tears associated with choroidal neovascularization, one tear associated with an RPE detachment without choroidal neovascularization, four iatrogenic tears occurring at krypton treatment of choroidal neovascularization, and four iatrogenic tears developing weeks to months after laser treatment of choroidal neovascularization. Eight patients had a final visual acuity of 20/100 or better, four were 20/200, and six were 20/400 or worse. Photocoagulation, particularly with the use of krypton red laser, may be modified on the basis of possible RPE tear formation. Heightened awareness of the possibility of inducing pigment epithelial rips should improve diagnosis and management of these cases.

Entities:  

Mesh:

Year:  1988        PMID: 2449643

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  13 in total

1.  Clinicopathological correlation of retinal pigment epithelial tears in exudative age related macular degeneration: pretear, tear, and scarred tear.

Authors:  B A Lafaut; S Aisenbrey; C Vanden Broecke; R Krott; C P Jonescu-Cuypers; S Reynders; K U Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Photodynamic therapy with verteporfin for retinal angiomatous proliferation.

Authors:  Francesco Boscia; Maurizio Battaglia Parodi; Claudio Furino; Michele Reibaldi; Carlo Sborgia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-09       Impact factor: 3.117

3.  Immediate loss of vision due to retinal pigment epithelial tear after anti-angiogenesis treatment of pigment epithelial detachment.

Authors:  Kurt Spiteri Cornish; Robert Harvey
Journal:  Digit J Ophthalmol       Date:  2011-08-18

4.  Change in vision after retinal pigment epithelium tear following the use of anti-VEGF therapy for age-related macular degeneration.

Authors:  Shane R Durkin; Lachlan D M Farmer; Susith Kulasekara; Jagjit Gilhotra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-08       Impact factor: 3.117

5.  Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.

Authors:  M Gutfleisch; B Heimes; M Schumacher; M Dietzel; A Lommatzsch; A Bird; D Pauleikhoff
Journal:  Eye (Lond)       Date:  2011-06-24       Impact factor: 3.775

6.  [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress].

Authors:  D Kook; A Wolf; A S Neubauer; C Haritoglou; S G Priglinger; A Kampik; M W Ulbig
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

7.  Choroidal thickness in retinal pigment epithelial tear as measured by spectral domain optical coherence tomography.

Authors:  Kavita V Bhavsar; Lauren Branchini; Heeral Shah; Caio V Regatieri; Jay S Duker
Journal:  Retina       Date:  2014-01       Impact factor: 4.256

8.  Retinal pigment epithelium tear after intravitreal aflibercept injection.

Authors:  Masaaki Saito; Mariko Kano; Kanako Itagaki; Yasuharu Oguchi; Tetsuju Sekiryu
Journal:  Clin Ophthalmol       Date:  2013-06-26

9.  RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD.

Authors:  Maria Andreea Gamulescu; Carsten Framme; Helmut Sachs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-21       Impact factor: 3.535

10.  A 56-year-old male with unilateral painless diminution of vision.

Authors:  Koushik Tripathy; Rohan Chawla; Vivek Kumar; Yog Raj Sharma; Pradeep Venkatesh
Journal:  Oman J Ophthalmol       Date:  2016 May-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.